Menu Search
Equities

Cerus Corp

CERS:NMQ

Cerus Corp

Actions
Health CareMedical Equipment and Services
  • Price (USD)1.68
  • Today's Change0.02 / 1.20%
  • Shares traded924.25k
  • 1 Year change-0.59%
  • Beta1.2081
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform3
Hold2
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Cerus Corp have a median target of 4.00, with a high estimate of 5.00 and a low estimate of 2.50. The median estimate represents a 139.52% increase from the last price of 1.67.
High199.4%5.00
Med139.5%4.00
Low49.7%2.50

Earnings history & estimates in USD

On Oct 30, 2024, Cerus Corp reported 3rd quarter 2024 losses of -0.02 per share. This result was in line with the consensus of the 6 analysts following the company and exceeded last year's 3rd quarter results by 50.00%.
The next earnings announcement is expected on Mar 03, 2025.
Average growth rate-62.92%
Cerus Corp reported annual 2023 losses of -0.21 per share on Mar 05, 2024.
Average growth rate+19.62%
More ▼

Revenue history & estimates in USD

Cerus Corporation had 3rd quarter 2024 revenues of 46.02m. This missed the 47.34m consensus estimate of the 5 analysts following the company. This was 48.57% above the prior year's 3rd quarter results.
Average growth rate+4.80%
Cerus Corporation had revenues for the full year 2023 of 156.37m. This was 3.51% below the prior year's results.
Average growth rate+14.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.